

ABSTRACT

The present invention relates generally to the field of immunomodulation and more specifically to compounds that exhibit Toll-like receptor 4 (TLR4) agonist activity. The invention provides novel compounds capable of stimulating or promoting an immune response, thereby offering potential therapeutic applications. In particular, the compounds may be useful in methods of promoting and/or maintain gastrointestinal health, as well as treating or preventing gastrointestinal diseases, such as IBD and colitis.

No suitable figure.